CNS Pharmaceuticals – Consensus Indicates Potential 321.3% Upside

Broker Ratings

CNS Pharmaceuticals found using ticker (CNSP) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 8 and 7 with a mean TP of 7.5. Given that the stocks previous close was at 1.78 this indicates there is a potential upside of 321.3%. The day 50 moving average is 2.21 and the 200 day moving average is 2.02. The company has a market cap of $42m. Visit the company website at:

CNS Pharmaceuticals, a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. CNS Pharmaceuticals was founded in 2017 and is based in Houston, Texas.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index